Nicotine protects against mu-opioid receptor antagonism by beta-funaltrexamine: evidence for nicotine-induced release of endogenous opioids in brain.

No abstract is available for this paper.

• Publication year

  1990

• Venue

  Neuroscience Letters

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 2164174
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential brain and peripheral nicotinic regulation of sympathoadrenal secretion.

  1989cited by this paper
• Opioid antinociceptive effects of delta-receptor antagonists.

  1988cited by this paper
• Tolerance to tobacco smoke- and nicotine-induced analgesia in rats.

  1988cited by this paper
• Nicotine-induced alterations in brain regional concentrations of native and cryptic Met- and Leu-enkephalin.

  1987cited by this paper
• Effects of stress and beta-funal trexamine pretreatment on morphine analgesia and opioid binding in rats.

  1987cited by this paper
• Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.

  1987cited by this paper
• Affinity labels for opioid receptors.

  1985cited by this paper
• Nicotinic receptor stimulation activates enkephalin release and biosynthesis in adrenal chromaffin cells

  1984cited by this paper
• Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine.

  1982cited by this paper
• The irreversible narcotic antagonistic and reversible agonistic properties of the fumaramate methyl ester derivative of naltrexone.

  1981cited by this paper
• Development and maintenance of morphine tolerance and dependence in the rat by scheduled access to morphine drinking solutions.

  1978cited by this paper
• Nicotine tolerance in rats; role of dose and dose interval

  1974cited by this paper

• New medications development for smoking cessation

  2023cites this paper
• Tobacco Use Disorder.

  2022cites this paper
• Ameliorative effects of varenicline and bupropion on morphine-induced conditioned place preference in rats

  2022cites this paper
• A determination of the aerosolization efficiency of drugs of abuse in a eutectic mixture with nicotine in electronic cigarettes.

  2022cites this paper
• Dopamine receptors in the anterior cingulate cortex implicate in nicotine enhanced morphine analgesia

  2021cites this paper
• Interindividual variability and lateralization of μ-opioid receptors in the human brain

  2020cites this paper
• Fagerstrom Test for Nicotine Dependence

  2020cites this paper
• Antagonism of Opioid μ Receptors for Smoking Cessation

  2019cites this paper
• Nicotine Gateway Effects on Adolescent Substance Use

  2019cites this paper
• The mechanism of chronic nicotine exposure and nicotine withdrawal on pain perception in an animal model.

  2019cites this paper
• Interindividual variability and lateralization of µ-opioid receptors in the human brain

  2019cites this paper
• Naloxone Antagonizes Soman‐induced Central Respiratory Depression in Rats

  2017cites this paper
• Endogenous opioid system: a promising target for future smoking cessation medications

  2017cites this paper
• Interactions between nicotine and drugs of abuse: a review of preclinical findings

  2017cites this paper
• Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.

  2016cites this paper
• Methadone's effect on nAChRs--a link between methadone use and smoking?

  2015cites this paper
• Enkephalin analog, cyclo[N(ε),N(β)-carbonyl-D-Lys(2),Dap(5)] enkephalinamide (cUENK6), inhibits the ethanol withdrawal-induced anxiety-like behavior in rats.

  2015cites this paper
• An in vitro analysis of striatal microcircuitry

  2015cites this paper
• Regional Brain [11C]carfentanil Binding Following Tobacco Smoking

  2015cites this paper
• Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder.

  2014cites this paper
• Genetic Variation of the Mu Opioid Receptor (OPRM1) and Dopamine D2 Receptor (DRD2) is Related to Smoking Differences in Patients with Schizophrenia but not Bipolar Disorder.

  2014cites this paper
• Buprenorphine maintenance and mu-opioid receptor availability in the treatment of opioid use disorder: implications for clinical use and policy.

  2014cites this paper
• Lack of association of OPRM1 genotype and smoking cessation.

  2013cites this paper
• Age-specific locomotor response to nicotine in yellow and mottled yellow Avy/a mice

  2013cites this paper
• Stress-Induced Activation of the Dynorphin/κ-Opioid Receptor System in the Amygdala Potentiates Nicotine Conditioned Place Preference

  2012cites this paper
• No al “hábito”, sí a la “adicción”. Análisis crítico de un eufemismo asociado al tabaco

  2012cites this paper
• [No to "habit", yes to "addiction". Critical analysis of a tobacco-associated euphemism].

  2012cites this paper
• Nitric oxide in the nucleus accumbens is involved in retrieval of inhibitory avoidance memory by nicotine.

  2012cites this paper
• OPRM1 genetic polymorphisms are associated with the plasma nicotine metabolite cotinine concentration in methadone maintenance patients: a cross sectional study

  2012cites this paper
• A systematic review of the A118G (Asn40Asp) variant of OPRM1 in relation to smoking initiation, nicotine dependence and smoking cessation.

  2012cites this paper
• Nicotine-induced changes of brain β-endorphin.

  2012cites this paper
• Biomarkers to optimize the treatment of nicotine dependence.

  2011cites this paper
• Activation of the opioid μ1, but not δ or κ, receptors is required for nicotine reinforcement in a rat model of drug self-administration.

  2011cites this paper
• Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers

  2011cites this paper
• Functional Characterization of the OPRM1 A118G Single Nucleotide Polymorphism in Mice

  2011cites this paper
• Nicotine and endogenous opioids: neurochemical and pharmacological evidence.

  2011cites this paper
• Venous plasma nicotine correlates of hormonal effects of tobacco smoking.

  2010cites this paper
• Nicotine Dependence and Pharmacogenetics

  2010cites this paper
• PET Imaging of Individual Differences in Regional Mu-Opioid Activation in Motivational Brain Circuitry.

  2010cites this paper
• OPRM1 SNP (A118G): involvement in disease development, treatment response, and animal models.

  2010cites this paper
• Nicotine Addiction: Past and Present

  2010cites this paper
• Interactions between nicotine and morphine in animal paradigms

  2009cites this paper
• Effects of chronic nicotine on behavioural and neurochemical responses to morphine

  2009cites this paper
• Imaging Human Brain Opioid Receptors: Applications to Substance Use Disorders

  2009cites this paper
• Pharmacogenetics of smoking cessation therapy

  2009cites this paper
• Naltrexone in Smoking Cessation: A Review of the Literature and Future Directions

  2009cites this paper
• Effects of chronic nicotine on behavioural and neurochemical responses to morphine

  2009cites this paper
• Effects of Smoking on Hormones, Brain, and Behavior

  2009cites this paper
• Nicotine dependence: biology, behavior, and treatment.

  2009influential citation
• Effects of rimonabant on the reinstatement of nicotine-conditioned place preference by drug priming in rats.

  2009cites this paper
• Nicotine dependence — human and animal studies, current pharmacotherapies and future perspectives

  2009cites this paper
• Beta-endorphin and drug-induced reward and reinforcement.

  2008cites this paper
• Neuroimaging, genetics and the treatment of nicotine addiction.

  2008cites this paper
• Repeated administration of nicotine attenuates the development of morphine tolerance and dependence in mice.

  2008cites this paper
• Morphine-nicotine interaction in conditioned place preference in mice after chronic nicotine exposure.

  2008cites this paper
• Conditioned Place Preference Induced by Licit Drugs: Establishment, Extinction, and Reinstatement

  2008cites this paper
• Differences in δ- and μ-Opioid Receptor Blockade Measured by Positron Emission Tomography in Naltrexone-Treated Recently Abstinent Alcohol-Dependent Subjects

  2008cites this paper
• Tobacco/nicotine and endogenous brain opioids.

  2008cites this paper
• Neuroadaptive changes in the mesocortical glutamatergic system during chronic nicotine self‐administration and after extinction in rats

  2008cites this paper
• Overview of the pharmacogenomics of cigarette smoking

  2007cites this paper
• Association of the mu-opioid receptor gene with smoking cessation

  2007cites this paper
• Naltrexone alteration of the nicotine-induced EEG and mood activation response in tobacco-deprived cigarette smokers.

  2007cites this paper
• Buprenorphine duration of action: mu-opioid receptor availability and pharmacokinetic and behavioral indices.

  2007cites this paper
• Smoking Modulation of μ-Opioid and Dopamine D2 Receptor-Mediated Neurotransmission in Humans

  2007cites this paper
• Translating basic science to improve pharmacotherapy for nicotine dependence.

  2007cites this paper
• Subchronic nicotine exposure in adolescence induces long-term effects on hippocampal and striatal cannabinoid-CB1 and mu-opioid receptors in rats.

  2007cites this paper
• Effects of ultra-low doses of nicotine on the expression of morphine-induced conditioned place preference in mice

  2006cites this paper
• Upregulation and Functionality of Neuronal Nicotinic Acetylcholine Receptors

  2006cites this paper
• Influence of acute and sub-chronic nicotine pretreatment on morphine state-dependent learning.

  2006cites this paper
• Nicotinic and opioid receptor interactions in nicotine addiction.

  2006cites this paper
• Current and emerging pharmacotherapies for treating tobacco dependence

  2006cites this paper
• Pharmacogenetic approaches to the treatment of nicotine dependence

  2006cites this paper
• CHAPTER 6 – Nicotine

  2006cites this paper
• Persistent exercise attenuates nicotine- but not clonidine-induced antinociception in female rats.

  2006cites this paper
• μ-Opioid Receptor and CREB Activation Are Required for Nicotine Reward

  2005cites this paper
• Nicotine-Induced Antinociception, Rewarding Effects, and Physical Dependence Are Decreased in Mice Lacking the Preproenkephalin Gene

  2005cites this paper
• Modulation of nicotine-induced analgesia by calcium agonist and antagonist in adult rats

  2005cites this paper
• Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm

  2005cites this paper
• Treating tobacco dependence: state of the science and new directions.

  2005cites this paper
• Pharmacogenetics and nicotine addiction treatment.

  2005cites this paper
• Reduced nicotine reward in obesity: cross-comparison in human and mouse

  2005cites this paper
• Adenosine receptor mediates nicotine-induced antinociception in formalin test.

  2005cites this paper
• Pharmacotherapy and pharmacogenetics of nicotine dependence.

  2005cites this paper
• Genetic Influences on Smoking: A Brief Review

  2005cites this paper
• The human mu opioid receptor gene in addictions

  2005cites this paper
• Endocrine effects of tobacco smoking

  2004cites this paper
• Potentiation of imipramine-induced antinociception by nicotine in the formalin test.

  2004cites this paper
• Nicotine dependence.

  2004cites this paper
• The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial

  2004cites this paper
• 3-0-Acetylmorphine-6O-Sulfate : A Potent , Centrally Acting Morphine Derivative

  2003cites this paper
• The Heritability of Antinociception: Common Pharmacogenetic Mediation of Five Neurochemically Distinct Analgesics

  2003cites this paper
• Naltrexone and nicotine patch smoking cessation: a preliminary study.

  2003cites this paper
• Cross-tolerance between morphine- and nicotine-induced conditioned place preference in mice.

  2003cites this paper
• Nicotine potentiation of morphine-induced catalepsy in mice.

  2002cites this paper
• Chronic daily ethanol and withdrawal: 3. Forebrain pro-opiomelanocortin gene expression and implications for dependence, relapse, and deprivation effect.

  2002cites this paper
• Chronic sucrose intake enhances nicotine-induced antinociception in female but not male Long-Evans rats.

  2001cites this paper
• The possible cross-tolerance between morphine- and nicotine-induced hypothermia in mice.

  2001cites this paper
• The opioid antagonist naltrexone inhibits activity and alters expression of α7 and α4β2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs

  2000cites this paper
• The opioid antagonist naltrexone inhibits activity and alters expression of alpha7 and alpha4beta2 nicotinic receptors in hippocampal neurons: implications for smoking cessation programs.

  2000cites this paper
• Potentiating effect of heroin on smoking rates

  2000cites this paper